Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC). Issue 9 (30th October 2018)

• Record Type: Journal Article
• Authors: Teo, Min; Scher, Howard
• Is Part Of: British journal of cancer. Volume 119:Issue 9(2018)
• Page Start: 1041
• Page End: 1043
• Publication Date: 2018-10-30
• Subjects: Cancer -- Periodicals; Cancer -- Research -- Periodicals; Tumors -- Periodicals; 616.994
• DOI: 10.1038/s41416-018-0239-y
• Languages: English
• ISSNs: 0007-0920

Abstract

Summary Abiraterone acetate plus prednisone is a standard treatment option for mCRPC. The phase II SWITCH trial showed that further prostate-specific antigen (PSA) responses can be obtained in a subset of patients when prednisone was switched to dexamethasone at progression. Here, we discuss the potential underlying mechanisms, including the activation of glucocorticoid receptors (GR) in progressive mCRPC and the implications for clinical practice.